Monoclonal anti-D antibodies to prevent alloimmunization: lessons from clinical trials

被引：26

作者：

Beliard, R ^{[1
]}

机构：

[1] LFB, F-91958 Les Ulis, Courtabaeuf, France

来源：

TRANSFUSION CLINIQUE ET BIOLOGIQUE | 2006年 / 13卷 / 1-2期

关键词：

anti-D; clearance; clinical trials; Fc gamma receptors; glycosylation; monoclonal antibodies; screening;

D O I：

10.1016/j.tracli.2006.03.013

中图分类号：

R5 [内科学];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

In the past 20 years, numerous monoclonal anti-D antibodies have been developed in order to replace the human plasma derived anti-D immunoglobulins, using different in vitro functional assays as screening methods. Some of these monoclonal antibodies have been evaluated in exploratory in vivo clinical trials, notably for their ability to mediate the clearance of D-positive red cells. A review of these reported trials is presented and the results are analyzed in the light of the newly published hypothesis conferring an important role to some Fc-Fc gamma R interactions and to the glycosylation-dependent potency of the monoclonal anti-D antibodies. (c) 2006 Elsevier SAS. All rights reserved.

引用

页码：58 / 64

页数：7

共 33 条

[1]

Evaluation of a panel of human monoclonal antibodies to D and exploration of the synergistic effects of blending IgG1 and IgG3 antibodies on their in vitro biologic function [J].